The emergence of radioimmunoscintigraphy for prostate cancer., PMID:17021623
Imaging of prostate cancer., PMID:17157630
Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer., PMID:17161036
Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma., PMID:17204699
Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide., PMID:17284381
Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer., PMID:17293236
Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion., PMID:17434109
Optimal cost-effective staging evaluations in prostate cancer., PMID:17459267
ProstaScint and its role in the diagnosis of prostate cancer., PMID:17620043
Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer., PMID:17826494
111In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its 111In-labelled murine antibody in the evaluation of prostate cancer., PMID:18034550
The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery., PMID:18090496
Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer., PMID:18164863
Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm., PMID:18163941
Indium-111 capromab pendetide in the management of recurrent prostate cancer., PMID:18279057
Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure., PMID:18343445
Disposable bioreactors: maturation into pharmaceutical glycoprotein manufacturing., PMID:19517075
Editorial comment., PMID:19616227
Editorial comment., PMID:19616247
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland., PMID:19616259
An elusive tumor in a man who has evidence of prostate cancer metastasis., PMID:19725410
Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy., PMID:19843189
In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT., PMID:20008977
111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer., PMID:20189846
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate., PMID:20434196
Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer., PMID:20961696
Editorial comment. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate., PMID:21056261
Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging., PMID:21477947
Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT., PMID:21493787
Evaluation of alternative methods for radiochemical purity testing of indium-111 capromab pendetide., PMID:21555286
Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer., PMID:21892036
Combined SPECT and Multidetector CT for Prostate Cancer Evaluations., PMID:22267999
Prostate-specific membrane antigen-based imaging., PMID:22658884
PSMA-targeted dendrimers: a patent evaluation (WO2012078534)., PMID:23581819
Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer., PMID:23595605
Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results., PMID:23993140
Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial., PMID:24144687
Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution., PMID:24718894
Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts., PMID:24764162
Detection of Recurrent Non-Hodgkin Lymphoma on In-111 Capromab Pendetide Imaging., PMID:25899589
The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis., PMID:25907118
Indium-111 Capromab Pendetide (ProstaScint(®)) Demonstrates Renal Cell Carcinoma and Aortocaval Nodal Metastases from Prostate Adenocarcinoma., PMID:26420994
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer., PMID:27679869
A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT., PMID:28332984
Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer., PMID:32721116
Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends., PMID:34771523
Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide, PMID: 17284381
Progress in SPECT/CT imaging of prostate cancer, PMID: 16866563
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate, PMID: 20434196
ProstaScint and its role in the diagnosis of prostate cancer, PMID: 17620043
Technical considerations for acquiring and processing indium-111 capromab pendetide images, PMID: 9291068
Disposable bioreactors: maturation into pharmaceutical glycoprotein manufacturing, PMID: 19517075
Capromab Pendetide immunoscintigraphy: connecting the dots for prostate cancer imaging, PMID: 10803317
Therapy with immunoglobulin: applications for monoclonal antibodies, PMID: 16878853
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer, PMID: 27679869
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group, PMID: 9598514
Imaging of prostate cancer, PMID: 17157630
123 I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid, PMID: 20641856
Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy, PMID: 19843189
Indium-111 Capromab Pendetide (ProstaScint(®)) Demonstrates Renal Cell Carcinoma and Aortocaval Nodal Metastases from Prostate Adenocarcinoma, PMID: 26420994
Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer, PMID: 9790041
123 I-Labeled (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedoic acid, PMID: 20641935
Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure, PMID: 18343445
Detection of Recurrent Non-Hodgkin Lymphoma on In-111 Capromab Pendetide Imaging, PMID: 25899589
Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm, PMID: 18163941
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland, PMID: 19616259
Prostate cancer abdominal metastases detected with indium-111 capromab pendetide, PMID: 9544673
A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy, PMID: 10850293
Technology insight: monoclonal antibody imaging of prostate cancer, PMID: 16607370
111In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its 111In-labelled murine antibody in the evaluation of prostate cancer, PMID: 18034550
In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT, PMID: 20008977
Editorial comment, PMID: 19616227
Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer, PMID: 20961696
Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer, PMID: 18164863
Prostate-specific membrane antigen-based imaging, PMID: 22658884
111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer, PMID: 20189846
Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial, PMID: 24144687
Current Clinical Applications of the In-capromab Pendetide Scan (ProstaScint(R) Scan, Cyt-356), PMID: 16985714
Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy, PMID: 12721246
Indium-111-capromab pendetide scans: an important test relevant to clinical decision making, PMID: 11248605
The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer, PMID: 12114876
Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging, PMID: 21477947
Evaluation of alternative methods for radiochemical purity testing of indium-111 capromab pendetide, PMID: 21555286
Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer, PMID: 17293236
Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer, PMID: 21892036
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy, PMID: 11920467
Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer, PMID: 10604708
Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT, PMID: 21493787
Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution, PMID: 24718894
Update on fused capromab pendetide imaging of prostate cancer, PMID: 15882479
Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer, PMID: 23595605
Indium-111 capromab pendetide in the management of recurrent prostate cancer, PMID: 18279057
Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer, PMID: 11272670
Capromab pendetide. A review of its use as an imaging agent in prostate cancer, PMID: 9571393
111 In-Capromab pendetide, PMID: 20641439
Capromab Pendetide imaging of prostate cancer, PMID: 10803318
For research use only. Not for human or drug use.
